Determinants of treatment outcomes in patients with multidrug-resistant TB

Int J Tuberc Lung Dis. 2022 Feb 1;26(2):126-132. doi: 10.5588/ijtld.21.0351.

Abstract

BACKGROUND: Treating multidrug-resistant TB (MDR-TB) remains challenging. However, the determinants and timing of poor outcomes during MDR-TB treatment are still poorly understood.METHODS: We conducted a retrospective cohort study on all adult MDR-TB patients treated at Persahabatan Hospital, Jakarta, Indonesia, between January 2013 and December 2016. Risk factors for poor outcomes were analysed using Cox regression.RESULTS: Death occurred at a median time of 6 months (IQR 4-14) and loss to follow-up (LTFU) at 7 months (IQR 3-11). In multivariate analysis, advanced age (aHR 2.91, 95% CI 1.21-6.96; P = 0.017 for age >60 years), having diabetes mellitus (aHR 2.18, 95% CI 1.25-3.82; P = 0.006) and HIV co-infection (aHR 3.73, 95% CI 1.14-12.23; P = 0.030) were predictive of poor outcome in the first 7 months of treatment, whereas history of LTFU (patients who were LTFU once: aHR 2.14, 95% CI 1.33-3.47; P = 0.002; patients who were LTFU more than once: aHR 3.61, 95% CI 1.68-7.77; P = 0.001) and baseline body mass index <18.5 kg/m² (aHR 1.98, 95% CI 1.10-3.56; P = 0.022) predicted poor outcome after 7 months of treatment.CONCLUSION: Different subsets of patients with MDR-TB are at risk of poor outcome at different times during treatment.

MeSH terms

  • Adult
  • Antitubercular Agents / therapeutic use
  • Coinfection* / drug therapy
  • HIV Infections* / drug therapy
  • HIV Infections* / epidemiology
  • Humans
  • Middle Aged
  • Retrospective Studies
  • Risk Factors
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

  • Antitubercular Agents